Paper · 36912538
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Hamdy FC and 30 others. N Engl J Med, 2023. Cited by 722 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. Papers, record 36912538. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36912538
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostate-Specific Antigen | Major topic |
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Androgen Antagonists | |
| Androgens | |
| Follow-Up Studies | |
| Prostatectomy | |
| Watchful Waiting | |
| Middle Aged | |
| Aged | |
| Radiotherapy | |
| Risk Assessment |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| C18281/A29019 | Cancer Research UK Integrative Cancer Epidemiology Program | PubMed | ||
| 15064 | Cancer Research UK | United Kingdom | PubMed | |
| 24432 | Cancer Research UK | United Kingdom | PubMed | |
| 22748 | Cancer Research UK | United Kingdom | PubMed | |
| National Institute for Health and Care Research | PubMed | |||
| Oxford NIHR Biomedical Research Centre | PubMed | |||
| 29019 | Cancer Research UK | United Kingdom | PubMed |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02044172 | Prostate Testing for Cancer and Treatment | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT07152067 | Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer | Background | ClinicalTrials.gov | |
| NCT07818395 | Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer | Results | ClinicalTrials.gov |
Comments and corrections7
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 37,117,110 | Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. | https://conductscience.org/library/papers/37117110 | PubMed |
| Comment in | 37,208,238 | Re: Fifteen-year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. | https://conductscience.org/library/papers/37208238 | PubMed |
| Comment in | 37,268,486 | Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. | https://conductscience.org/library/papers/37268486 | PubMed |
| Comment in | 37,334,535 | Urologic Oncology: Prostate Cancer. | https://conductscience.org/library/papers/37334535 | PubMed |
| Comment in | 37,407,012 | Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. | https://conductscience.org/library/papers/37407012 | PubMed |
| Comment in | 37,407,013 | Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply. | https://conductscience.org/library/papers/37407013 | PubMed |
| Comment in | 37,684,177 | Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58. | https://conductscience.org/library/papers/37684177 | PubMed |
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by423
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 722 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,980,759 | Opportunistic PSA testing is not the safe alternative : Why Austria's non-policy on prostate cancer screening maximizes harm and forfeits the benefits. | Wien Klin Wochenschr | 2026 | https://conductscience.org/library/papers/42980759 | PubMed |
| 42,961,521 | Local treatment vs. years of life lost in intermediate-risk prostate cancer. | World J Urol | 2026 | https://conductscience.org/library/papers/42961521 | PubMed |
| 42,959,402 | Peri-urethral calcifications as a potential biomarker for acute genitourinary toxicity following prostate stereotactic body radiotherapy. | Clin Transl Radiat Oncol | 2027 | https://conductscience.org/library/papers/42959402 | PubMed |
| 42,938,910 | Active Surveillance in Low- and Intermediate-Risk Prostate Cancer: Comparative Oncologic Safety, Patient Selection, and Predictors of Treatment Conversion in the Era of Multiparametric MRI: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938910 | PubMed |
| 42,930,166 | Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930166 | PubMed |
| 42,923,343 | Challenges in Managing Synchronous Advanced Prostate and Pancreatic Cancers: A Case Report. | Case Rep Oncol | 2026 | https://conductscience.org/library/papers/42923343 | PubMed |
| 42,905,202 | Subnational inequalities and socioeconomic gradients in prostate cancer burden across Mexico, 2000-2023. | Cancer Causes Control | 2026 | https://conductscience.org/library/papers/42905202 | PubMed |
| 42,878,878 | EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence. | World J Urol | 2026 | https://conductscience.org/library/papers/42878878 | PubMed |
| 42,869,964 | Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis. | Prostate Cancer Prostatic Dis | 2026 | https://conductscience.org/library/papers/42869964 | PubMed |
| 42,783,413 | Precision Diagnostics in Prostate Cancer: Integrating Biomarkers, Imaging, Genomics, and Artificial Intelligence in Contemporary United States Practice. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42783413 | PubMed |
1 to 10 of 423
See all 423 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| ISRCTN | ISRCTN20141297 |
Source ISRCTN
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36912538
GET https://conductscience.org/api/papers/v1/36912538/authors?page=2